Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer

Identification of an Exon 4-Deletion Variant of Epidermal Growth Factor Receptor with Increased Metastasis-Promoting Capacity

(2015) Hai Wang et al.   NEOPLASIA

Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion

(2012) Xiaoxia Hu et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression

(2012) Junye Liu et al.   BMC CANCER

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase I Trial of Intraperitoneal Pemetrexed, Cisplatin, and Paclitaxel in Optimally Debulked Ovarian Cancer

(2012) S. K. Chambers et al.   CLINICAL CANCER RESEARCH

Epidermal growth factor receptor inhibits colitis-associated cancer in mice

(2012) Philip E. Dubé et al.   JOURNAL OF CLINICAL INVESTIGATION

BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin

(2012) Nisha Bansal et al.   Journal of Gynecologic Oncology

Relaxin induces matrix-metalloproteinases-9 and -13 via RXFP1: Induction of MMP-9 involves the PI3K, ERK, Akt and PKC-ζ pathways

(2012) Nisar Ahmad et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival

(2011) D. C. Marchion et al.   CLINICAL CANCER RESEARCH

Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation

(2011) Hai Wang et al.   FASEB JOURNAL

Phase II Study of Intraperitoneal Paclitaxel Plus Cisplatin and Intravenous Paclitaxel Plus Bevacizumab As Adjuvant Treatment of Optimal Stage II/III Epithelial Ovarian Cancer

(2011) Jason A. Konner et al.   JOURNAL OF CLINICAL ONCOLOGY

Heparan Sulfate Proteoglycans Mediate Interstitial Flow Mechanotransduction Regulating MMP-13 Expression and Cell Motility via FAK-ERK in 3D Collagen

(2011) Zhong-Dong Shi et al.   PLoS One

Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy

(2010) Gur Pines et al.   FEBS LETTERS

Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth

(2010) Paul H. Huang et al.   Molecular BioSystems

EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism

(2010) G Pines et al.   ONCOGENE

Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities

(2009) Helmout Modjtahedi et al.   ANTI-CANCER DRUGS

Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma

(2009) Huamao Wang et al.   CANCER LETTERS

BAD: undertaker by night, candyman by day

(2009) N N Danial   ONCOGENE

Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity

(2008) Zhang Weihua et al.   CANCER CELL

Tumour cell survival signalling by the ERK1/2 pathway

(2008) K Balmanno et al.   CELL DEATH AND DIFFERENTIATION